Previous Mtb challenge studies have demonstrated that RhCMV/TB vaccination resulted in circulating Mtb-specific CD4+ and CD8+ T cells, and RMs with subcutaneous RhCMV/TB vaccination showed reduced Mtb infection and disease (based on both Mtb culture and pathologic score) by nearly 70% compared to unvaccinated controls (7). The gene discussed is CD8A; the disease is tuberculosis.